These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 11367488)

  • 1. Any toxic relief in sight? The induction/maintenance approach to therapy.
    Gomez E
    Newsline People AIDS Coalit N Y; 1998 Sep; ():33. PubMed ID: 11367488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Amsterdam duration of antiretroviral medication (ADAM)--study: induction-suppression treatment in HIV-I infection, preliminary results].
    Reijers MH; Weverling GJ; Jurriaans S; Wit FW; van Leeuwen R; Bruisten SM; Frissen PH; Weigel HM; Mulder JW; ten Kate RW; de Wolf F; Schuitemaker H; Lange JM
    Ned Tijdschr Geneeskd; 1998 Oct; 142(40):2230. PubMed ID: 10049092
    [No Abstract]   [Full Text] [Related]  

  • 4. Spring cleaning in trial land.
    Gilden D
    GMHC Treat Issues; 1997 Mar; 11(3):4-7. PubMed ID: 11364275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update from the 5th Conference on Retroviruses and Opportunistic Infections.
    Vazquez E
    Posit Aware; 1998; 9(3):21-3. PubMed ID: 11365483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stavudine, lamivudine plus novel protease inhibitor therapy in antiretroviral-naive HIV-infected individuals treated for 24 weeks.
    Murphy RL
    Antivir Ther; 1999; 4 Suppl 3():85-7. PubMed ID: 16021877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protease inhibitor trials moving to next phase.
    AIDS Alert; 1995 Aug; 10(8):100-1. PubMed ID: 11362675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term efficacy and safety of twice-daily saquinavir soft gelatin capsules (SGC), with or without nelfinavir, and three times daily saquinavir-SGC, in triple combination therapy for HIV infection: 100-week follow-up.
    Greenberg RN; Feinberg J; Goodrich J; Pilson RS; Siemon-Hryczyk P
    Antivir Ther; 2003 Feb; 8(1):37-42. PubMed ID: 12713062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nelfinavir - major trial results at retroviruses conference.
    AIDS Treat News; 1997 Feb; (No 265):3-4. PubMed ID: 11364240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Head-to-head study of protease inhibitors.
    AIDS Patient Care STDS; 1998 Jan; 12(1):63-4. PubMed ID: 11361890
    [No Abstract]   [Full Text] [Related]  

  • 11. Soft gel saquinavir has high exposure.
    AIDS Alert; 1997 Dec; 12(12):143-4. PubMed ID: 11364835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interrupting HAART; Hydroxyurea; five+ drug therapy - report from the RIGHT Conference.
    Levin J
    AIDS Treat News; 1999 May; (No 318):3-4. PubMed ID: 11366456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug research shows easier dosing, new combinations are making gains.
    AIDS Alert; 1998 Apr; 13(4):37-9. PubMed ID: 11365139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quadruple-2 protease inhibitors (PI)-therapy does not accelerate viral decay and suppression in PI-naive HIV-1 infected patients with severe immunosuppression and high viral load as compared with standard triple therapy.
    Portilla J; Boix V; Garcia-Henarejos JA; Llopis C; Martínez-Madrid O; Gimeno A; Sánchez-Paya J; Merino E
    Int J STD AIDS; 2005 Dec; 16(12):807-10. PubMed ID: 16336763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Observational study on the efficacy of the application of two classical regimens of triple antiretroviral therapy].
    Eiros Bouza JM; Ortega Lafont M; Ortiz de Lejarazu R; Bachiller Luque P; de Luis Román DA
    An Med Interna; 2003 May; 20(5):239-42. PubMed ID: 12831297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
    Mootsikapun P; Chetchotisakd P; Anunnatsiri S; Boonyaprawit P
    Antivir Ther; 2005; 10(8):911-6. PubMed ID: 16430196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adherence over 48 weeks in an antiretroviral clinical trial: variable within patients, affected by toxicities and independently predictive of virological response.
    Nieuwkerk P; Gisolf E; Sprangers M; Danner S;
    Antivir Ther; 2001 Jun; 6(2):97-103. PubMed ID: 11491422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AVANTI 3: a randomized, double-blind trial to compare the efficacy and safety of lamivudine plus zidovudine versus lamivudine plus zidovudine plus nelfinavir in HIV-1-infected antiretroviral-naive patients.
    Gartland M;
    Antivir Ther; 2001 Jun; 6(2):127-34. PubMed ID: 11491417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful simplification of HAART in patients with acute primary HIV infection.
    Sinicco A; Bonora S; Arnaudo I; Zeme DA; Audagnotto S; Raiteri R; Di Perri G
    J Biol Regul Homeost Agents; 2002; 16(1):69-72. PubMed ID: 12003178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine.
    Kempf DJ; King MS; Bernstein B; Cernohous P; Bauer E; Moseley J; Gu K; Hsu A; Brun S; Sun E
    J Infect Dis; 2004 Jan; 189(1):51-60. PubMed ID: 14702153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.